Compare Stocks → The asset beating inflation by 4x (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:CALANASDAQ:CNCENASDAQ:HOOKOTCMKTS:NWBO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.16-1.2%$3.70$1.42▼$11.97$247.15M1.45588,668 shs319,625 shsCALACalithera Biosciences$0.02$0.02$0.01▼$0.50$97KN/A799 shs57 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AHOOKHookipa Pharma$0.93+1.1%$0.77$0.41▼$2.05$92.04M0.921.36 million shs324,371 shsNWBONorthwest Biotherapeutics$0.46-2.1%$0.52$0.40▼$1.09$554.88M-0.641.26 million shs1.27 million shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-1.19%+5.85%+0.24%+30.82%-59.14%CALACalithera Biosciences0.00%0.00%0.00%-36.00%-20.00%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HOOKHookipa Pharma+1.34%+4.13%+20.96%+36.79%-22.48%NWBONorthwest Biotherapeutics0.00%-2.32%-14.82%-15.30%-22.34%Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.5718 of 5 stars3.52.00.00.01.62.50.0CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHOOKHookipa Pharma2.6837 of 5 stars3.53.00.00.03.31.70.6NWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33124.36% UpsideCALACalithera BiosciencesN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AHOOKHookipa Pharma3.00Buy$4.67401.68% UpsideNWBONorthwest BiotherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ALDX, HOOK, NWBO, CNCE, and CALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/26/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.50 ➝ $5.004/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.50(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/ACALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.05CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58HOOKHookipa Pharma$20.13M4.57N/AN/A$0.91 per share1.02NWBONorthwest Biotherapeutics$1.93M287.50N/AN/A($0.06) per share-7.67Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.51N/AN/AN/AN/A-24.16%-19.95%8/1/2024 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AHOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)NWBONorthwest Biotherapeutics-$62.60M-$0.06N/A∞N/A-3,240.11%N/A-207.51%5/8/2024 (Estimated)Latest ALDX, HOOK, NWBO, CNCE, and CALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A3/5/2024Q4 2023NWBONorthwest BiotherapeuticsN/A-$0.02-$0.02-$0.02N/A$0.45 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64CALACalithera BiosciencesN/AN/AN/ACNCEConcert PharmaceuticalsN/A9.039.03HOOKHookipa PharmaN/A3.503.50NWBONorthwest BiotherapeuticsN/A0.090.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CALACalithera BiosciencesN/ACNCEConcert Pharmaceuticals70.63%HOOKHookipa Pharma63.88%NWBONorthwest Biotherapeutics0.04%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%CALACalithera Biosciences6.60%CNCEConcert Pharmaceuticals11.33%HOOKHookipa Pharma5.82%NWBONorthwest Biotherapeutics9.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million55.08 millionOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableHOOKHookipa Pharma5698.95 million93.19 millionOptionableNWBONorthwest Biotherapeutics251.21 billion1.09 billionNot OptionableALDX, HOOK, NWBO, CNCE, and CALA HeadlinesSourceHeadlineNorthwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average of $0.64americanbankingnews.com - May 2 at 4:48 AMNorthwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.65americanbankingnews.com - April 24 at 4:06 AMNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directorsprnewswire.com - March 21 at 11:09 AM‘Spoofing’ case might draw back curtain on high-speed trading firmsft.com - March 2 at 10:11 AMNorthwest Biotherapeutics, Inc. (NWBO)uk.finance.yahoo.com - February 29 at 2:53 PMNorthwest Biotherapeutics Stock (OTC:NWBO), Short Interest Reportbenzinga.com - February 23 at 12:07 AMNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certificationfinance.yahoo.com - February 7 at 4:37 PMNorthwest Biotherapeutics submits marketing application to UK MHRA for DCVax-Lmsn.com - December 22 at 10:28 AMNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastomafinanznachrichten.de - December 21 at 12:53 PMNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastomafinance.yahoo.com - December 21 at 12:53 PMNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Applicationfinance.yahoo.com - November 22 at 2:22 PMNorthwest Biotherapeutics Inc NWBOmorningstar.com - October 31 at 12:12 PMNorthwest Bio: Another Small Filing Delaymsn.com - October 14 at 10:44 AMNW Bio dips on announcing delay in submission of marketing application for DCVaxseekingalpha.com - October 13 at 12:56 PMNorthwest Biotherapeutics Shares Slide on Application Delaymarketwatch.com - October 13 at 12:56 PMNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Applicationfinance.yahoo.com - October 13 at 12:56 PMPolice searching for suspects in Northwest DC shootingwjla.com - October 10 at 10:28 AMNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Boardfinance.yahoo.com - September 12 at 6:48 PMSports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWTbasketballinsiders.com - August 30 at 6:42 PMNorthwest Bio: Is There Ever Going To Be A Right Time?msn.com - August 17 at 9:29 PMNorthwest Missouri State Universityusnews.com - August 6 at 5:59 PMNorthwest Hospitalhealth.usnews.com - August 4 at 6:51 PMStanding Stone Circles: The most ancient builders of Northwest Arabianationalgeographic.com - August 3 at 8:41 AMSiloam Springs Newsnwaonline.com - July 22 at 1:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Calithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Hookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Northwest BiotherapeuticsOTCMKTS:NWBONorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.